题名

支持性照護計劃對使用EGFR-TKIs之非小細胞肺癌病人皮膚疾患與生活品質成效追蹤

并列篇名

The Effects of Supportive Care Programs on Skin Disorders and Quality of Life in Patients With Non-Small Cell Lung Cancer Using EGFR-TKIs

DOI

10.6880/TJON.202112_21(2).04

作者

邱惠英(Hui-Ying Chiu);林佑樺(Yu-Hua Lin);王儷螢(Li-Ying Wang);林孟志(Meng-Chih Lin);陳彥豪(Yen-Hao Chen);王金洲(Chin-Chou Wang)

关键词

非小細胞肺癌 ; EGFR-TKIs標靶治療 ; 皮膚疾患 ; 生活品質 ; non-small cell lung cancer ; EGFR-TKIs ; skin disorders ; quality of life

期刊名称

腫瘤護理雜誌

卷期/出版年月

21卷2期(2021 / 12 / 01)

页次

35 - 51

内容语文

繁體中文

中文摘要

背景:肺癌病人接受表皮生長因子受體酪胺酸激酶抑制劑(EGFR-TKIs)治療,易造成皮膚副作用且與生活品質問題,然其縱貫性變化觀察則較闕如。目的:了解肺癌病人服用EGFR-TKIs藥物後之皮膚疾患,並檢視支持性照護對皮膚疾患與生活品質之成效。方法:採類實驗設計,立意取樣以122位初診斷肺癌首次接受標靶治療者為研究對象,先收對照組61位,再收實驗組61位,兩組於標靶治療前進行資料收集與皮膚照護衛教,分別於服藥後二週(Time 1, T1)、六週(Time 2, T2)、十週(Time 3, T3)及二十四週(Time 4, T4)進行四次後測,實驗組於每次後測後,重複提供支持性照護。測量工具為皮膚副作用及嚴重度評估表、皮膚疾患生活品質量表。結果:整體皮膚疾患於第六週呈現較嚴重,其發生率依序為皮膚瘙癢、丘疹膿皰疹、皮膚乾燥及甲溝炎。以平均數比較顯示實驗組四次後測整體生活品質和症狀、功能和情緒等構面得分均優於對照組。經概化估計方程模式(GEE)檢視組別與時間之成效,顯示治療後第六週,實驗組的整體生活品質(p = .002)、功能(p = .000)和情緒(p = .021)構面顯著優於對照組。結論/實務運用:支持性照護介入在治療後第六週起顯著有效改善接受EGFR-TKIs藥物治療肺癌病人之生活品質。本結果建議於肺癌病人接受治療六週期間應密切追蹤病人皮膚疾患,及時提供支持性照護,進而改善病人生活品質。

英文摘要

Background: Patients with non-small cell lung cancer (NSCLC) treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are often exposed to diverse skin disorders and decrease in quality of life. Thus far, the longitudinal follow-up on the skin change is rare. Purpose: To understand the skin diseases of NSCLC patients on EGFR-TKIs, and to examine the effect on quality of life from the supportive care programs. Methods: This is a quasi-experimental study. 122 patients with NSCLC were enrolled in this study and divided into two groups (experimental and controlled group). During a 24 weeks of the experimental course, data collection and patient education on skin care was done (pre-treatment) first, followed by four times of evaluations (post-treatment) after medication at the second week point (Time 1, T1), sixth week (Time 2, T2), tenth week (Time 3, T3) and the twenty-fourth week point (Time 4, T4), respectively. The experimental group received repeated post-treatment supportive care for 4 times. The outcome measurements criteria included the skin treatment side effects and severity assessment, and quality of life. Results: The incidence of skin disorders was highest in the sixth week, such as, acneiform rash, itchy skin, pruritus, dry skin (xerosis), and paronychia. The GEE model showed that after six weeks of EGFR-TKIs, the experimental group did significantly better in the overall quality of life (p = .002), functional dimension (p = .000), and emotional dimension (p = .021) than the controlled group at same period. Conclusions/Practical Implications: Supportive care can effectively improve the quality of life of NSCLC patients receiving EGFR-TKIs during the sixth week after treatment. It is recommended that patients should be closely monitored to receive timely supportive care.

主题分类 醫藥衛生 > 預防保健與衛生學
醫藥衛生 > 內科
醫藥衛生 > 社會醫學
参考文献
  1. Chan, J. C.,Lee, Y. H.,Liu, C. Y.,Shih, H. H.,Tsay, P. K.,Tang, W. R.(2019).A correlational study of skin toxicity and quality of life in patients with advanced lung cancer receiving targeted therapy.Journal of Nursing Research,27(6),e51.
    連結:
  2. 邱惠英,林佑樺,王金洲,陳婉宜,張晃智,林孟志(2016)。肺癌化學治療後病人照護需求與相關因素之探討。護理雜誌,63(3),62-72。
    連結:
  3. 張黎露,朱家瑜,姜紹清,許麗珠,黃國埕,周文珊,張美娟,侯秀香(2015)。標靶治療藥品之皮膚毒性預防及照護指引。腫瘤護理雜誌增訂刊,15,47-80。
    連結:
  4. Aw, D. C.,Tan, E. H.,Chin, T. M.,Lim, H. L.,Lee, H. Y.,Soo, R. A.(2018).Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities.Asia-Pacific Journal of Clinical Oncology,14(1),23-31.
  5. Chren, M. M.(1997).Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin disease.Archives of Dermatology,133,1433-1440.
  6. Chren, M. M.,Lasek, R. J.,Quinn, L. M.,Mostow, E. N.,Zyzanski, S. J.(1996).Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness.Journal of Investigative Dermatology,107(5),707-713.
  7. Chu, C. Y.,Chen, K. Y.,Chang, J. W. C.,Wei, Y. F.,Lee, C. H.,Wang, W. M.(2017).Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities.Journal of the Formosan Medical Association,116(6),413-423.
  8. Donald, P. B.,Digant, G.,Edgar, D. S.(2011).Quality of life assessment as a predictor of survival in non-small cell lung cancer.BMC Cancer,11,353.
  9. Fitch, M.(1994).Providing supportive care for individuals living with cancer.Toronto:Ontario Cancer Treatment and Research Foundation.
  10. Hirsh, V.(2011).Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer.Current Oncology,18(3),126-138.
  11. Joshi, S. S.,Ortiz, S.,Witherspoon, J. N.,Rademaker, A.,West, D. P.,Anderson, R.,Rosenbaum, S. E.,Lacouture, M. E.(2010).Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.Cancer,116(16),3916-3923.
  12. Kozuki, T.(2016).Skin problems and EGFR-tyrosine kinase inhibitor.Japanese Journal of Clinical Oncology,46(4),291-298.
  13. Lacouture, M. E.,Anadkat, M. J.,Bensadoun, R. J.,Bryce, J.,Chan, A.,Epstein, J. B.,Eaby-Sandy, B.,Murphy, B. A.(2011).Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.Supportive Care in Cancer,19(8),1079-1095.
  14. Lacouture, M. E.,Anadkat, M.,Jatoi, A.,Garawin, T.,Bohac, C.,Mitchell, E.(2018).Dermatologic toxicity occurring during anti-EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: a systematic review.Clinical Colorectal Cancer,17(2),85-96.
  15. Lupu, I.,Voiculescu, V. M.,Bacalbasa, N.,Cojocaru, I.,Vrancian, V.,Giurcaneanu, C.(2016).Cutaneous complications of molecular targeted therapy used in oncology.Journal of Medicine and Life,9(1),19.
  16. Maguire, R.,Papadopoulou, C.,Kotronoulas, G.,Simpson, M. F.,Mcphelim, J.,Irvine, L.(2013).A systematic review of supportive care needs of people living with lung cancer.European Journal of Oncology Nursing,17(4),449-464.
  17. Masago, K.,Imamichi, F.,Masuda, Y.,Ariga, N.,Fujitomi, K.,Fukumine, Y.,Hatakenaka, K.,Fujita, S.,Katakami, N.(2018).Team management of skin rash associated with use of epidermal growth factor receptor-tyrosine kinase inhibitors.Asia-Pacific Journal of Oncology Nursing,5(4),430-434.
  18. Melosky, B.,Anderson, H.,Burkes, R. L.,Chu, Q.,Hao, D.,Ho, V.,Ho, C.,Lam, W.,Lee, C. W.,Leighl, N, B.,Murray, N.,Sun, S.,Winston, R.,Laskin, J. J.(2016).Pan canadian rash trial: A randomized phase III trial evaluating the impact of a prophylactic skin treatment regimen on epidermal growth factor receptor-tyrosine kinase inhibitor- induced skin toxicities in patient with metastatic lung cancer.Journal of Clinical Oncology,34(8),810-815.
  19. National Cancer Institutes. (2010). Common Terminology Criteria for Adverse Events (CTCAE) Version 4.3, Retrieved from https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_4.03.xlsx
  20. NCCN Clinical Practice Guideline in Oncology. Non- small cell lung cancer (2021, March 29). National Comprehensive Cancer Network.Retrieved from https://www.nccn.org/professionals/ physician_gls/ pdf/nscl.pdf
  21. Olver, I.,Keefe, D.,Herrstedt, J.,Warr, D.,Roila, F.,Ripamonti, C.(2020).Supportive care in cancer-a MASCC perspective.Supportive Care in Cancer,28,3467-3475.
  22. Pugliese, S. B.,Neal, J. W.,Kwong, B. Y.(2015).Management of dermatologic complications of lung cancer therapies.Current treatment Options in Oncology,16(10),50.
  23. Rigdon, A. S.(2010).Development of patient education for older adults receiving chemotherapy.Clinical Journal of Oncology Nursing,14(4),433-441.
  24. Rosen, A. C.,Case, E. C.,Dusza, S. W.,Balagula, Y.,Gordon, J.,West, D. P.,Lacouture, M. E.(2013).Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic.American jourmal of Clinical Dermatology,14(4),327-333.
  25. Tischer, B.,Huber. R.,Kraemer, M.,Lacouture. M. E.(2017).Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.Supportive Care in Cancer,25(2),651-660.
  26. Tseng, L. C.,Chen, K. H.,Wang, C. L.,Weng, L. C.(2020).Effects of tyrosine kinaseinhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer.Medicine,99(23),e20510.
  27. Velikova, G.,Booth, L.,Smith, A. B.,Brown, P. M.,Lynch, P.,Brown, J. M.,Selby, P. J.(2018).Measuring quality of life in routine oncology practice.Journal of Clinical Oncology,22(4),714-724.
  28. 柯獻欽,鄭高珍(2018)。晚期非小細胞肺癌之化學治療與標靶治療。內科學誌,29(3),143-152。
  29. 衛生福利部中央衛生健康保險署(2020,6月1日),藥品給付規定,第九節抗癌瘤藥物。https://www.nhi.gov.tw/Content_List.aspx?n = E70D4F1BD029DC37&topn=3FC7D09599D25979
  30. 衛生福利部國民健康屬(2021,3月22日),107年癌症登記報告。https://www.hpa.gov.tw/Pages/List.aspx?nodeid=269
  31. 衛生福利部統計處(2021,6月18日),109年主要癌症死亡統計。https://dep.mohw.gov.tw/dos/cp-1735-3242-113.html
被引用次数
  1. 林佑樺,吳麗珠(2023)。支持性關懷對腦腫瘤術後病人之症狀困擾、護理需求與憂鬱成效之前驅性研究。護理雜誌,70(1),48-59。